Intellia Therapeutics, Inc. (NTLA) Q4 FY25 Earnings Call

Mid-2026 Halo data is the key catalyst, while unresolved Magnitude safety and regulatory issues remain the principal overhang.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-01
Length59 minutes
EPS$-0.83
EPS consensus$-0.99
Revenue$23.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26

Read the full Q4 FY25 earnings call transcript

All NTLA earnings · Back to NTLA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.